Every material Form 8-K Regeneron Pharmaceuticals filed with the SEC in 2024, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Regeneron reported third quarter 2024 revenue of $3.72 billion, up 11% from a year earlier, and GAAP diluted earnings per share of $11.54, up 30%. Non-GAAP diluted EPS rose 8% to $12.46, and the company cut the top end of its non-GAAP SG&A guidance while raising its capital expenditure guidance.
Total revenues rose 11% to $3.72 billion; GAAP net income rose 33% to $1.34 billion.
Non-GAAP diluted EPS rose 8% to $12.46, including an unfavorable $0.43 impact from acquired IPR&D charges.
Repurchased $738 million of stock in the quarter; $2.9 billion remained under the buyback program at September 30, 2024.
Full-year 2024 capital expenditure guidance was raised to $750–$820 million from $700–$740 million.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Regeneron Pharmaceuticals filing is on SEC EDGAR ↗. 8-K briefs of other companies →